Abstract:Inactivation of p53 is present in almost every tumor, and hence, p53-reactivation strategies are an important aspect of cancer therapy. Common mechanisms for p53 loss in cancer include expression of p53-negative regulators such as MDM2, which mediate the degradation of wildtype p53 (p53 alpha), and inactivating mutations in the TP53 gene. Currently, approaches to overcome p53 deficiency in these cancers are limited. Here, using non-small cell lung cancer and glioblastoma multiforme cell line models, we show that two alternatively spliced, functional truncated isoforms of p53 (p53 beta and p53 gamma , comprising exons 1 to 9 beta or 9 gamma , respectively) and that lack the C-terminal MDM2-binding domain have markedly reduced susceptibility to MDM2-mediated degradation but are highly susceptible to nonsense-mediated decay (NMD), a regulator of aberrant mRNA stability. In cancer cells harboring MDM2 overexpression or TP53 mutations downstream of exon 9, NMD inhibition markedly upregulates p53 beta and p53 gamma and restores activation of the p53 pathway. Consistent with p53 pathway activation, NMD inhibition induces tumor suppressive activities such as apoptosis, reduced cell viability, and enhanced tumor radiosensitivity, in a relatively p53-dependent manner. In addition, NMD inhibition also inhibits tumor growth in a MDM2-overexpressing xenograft tumor model. These results identify NMD inhibition as a novel therapeutic strategy for restoration of p53 function in p53-deficient tumors bearing MDM2 over expression or p53 mutations downstream of exon 9, subgroups that comprise approximately 6% of all cancers.

Mutant p53–Nrf2 axis regulates the proteasome machinery in cancer

Mutant p53 tunes the NRF2-dependent antioxidant response to support survival of cancer cells

Inhibition of nonsense-mediated decay rescues p53/ isoform expression and activates the p53 pathway in and select-mutant cancers

Inhibition of Nonsense-Mediated Decay Rescues P53β/γ Isoform Expression and Activates the P53 Pathway in MDM2-overexpressing and Select P53-Mutant Cancers

Proteasome inhibition paradoxically degrades gain-of-function mutant p53 R273H in NSCLC and could have therapeutic implications

Mutant p53 as a guardian of the cancer cell

Small Molecule Agents Targeting the P53-Mdm2 Pathway for Cancer Therapy

Modeling the Etiology of p53-mutated Cancer Cells

Targeting mutant p53-R248W reactivates WT p53 function and alters the onco-metabolic profile

Differential Regulation of the REGγ–proteasome Pathway by P53/tgf-Β Signalling and Mutant P53 in Cancer Cells

Promising Proteolysis-Targeting Chimera for Mutant p53-R175H

Recent Advances on Mutant p53: Unveiling Novel Oncogenic Roles, Degradation Pathways, and Therapeutic Interventions

Mutant p53 drives cancer chemotherapy resistance due to loss of function on activating transcription of PUMA

Differential Regulation Of The Reg Gamma-Proteasome Pathway By P53/Tgf-Beta Signalling And Mutant P53 In Cancer Cells

Mutant p53 protects triple-negative breast adenocarcinomas from ferroptosis in vivo

Mutant p53 in cancer therapy-the barrier or the path.

Mutant p53-Associated Molecular Mechanisms of ROS Regulation in Cancer Cells

Targeting mutant p53 stabilization for cancer therapy

Mutant p53 in Cancer Progression and Targeted Therapies

Mutant p53 achieved Gain-of-Function by promoting tumor growth and immune escape through PHLPP2/AKT/PD-L1 pathway

Disrupting the interaction between a p53 gain‐of‐function mutant and the transcriptional co‐activator PC4 reverses drug resistance in cancer cells